Treats clinically important hypotension resulting primarily from vasodilation in the…. ANDA 211078, held by Amneal. Phenylephrine Hydrochloride.
As of Nov 16, 2026, ANDA 211078 (Phenylephrine Hydrochloride), held by Amneal, was first approved by FDA on Jul 19, 2018, with 2 approved supplements and 0 published complete response letters.
Phenylephrine hydrochloride injection, 10 mg/mL is indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 19, 2018 | Original application | Approved | None posted |
| Phenylephrine Hydrochloride50MG/5ML (10MG/ML) · solution;intravenous | Phenylephrine Hydrochloride | Rx |
| Phenylephrine Hydrochloride100MG/10ML (10MG/ML) · solution;intravenous | Phenylephrine Hydrochloride | Rx |
| Aug 12, 2020 | Supplement 3Labeling · Standard review | Approved | None posted |
| Aug 12, 2020 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jul 19, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters